Price
Frequently asked questions
What is CEL-SCI's market capitalization?
What is the Earnings Per Share (EPS) for CEL-SCI?
What are the analyst ratings and target price for CEL-SCI's stock?
What is the EBITDA for CEL-SCI?
What is the free cash flow of CEL-SCI?
What is the 5-year beta of CEL-SCI's stock?
How many employees does CEL-SCI have, and what sector and industry does it belong to?
What is the free float of CEL-SCI's shares?
Financials
Market Cap
$44.28M5Y beta
0.62EPS (TTM)
-$0.581Free Float
59.70MEBITDA (TTM)
-$23.72MFree Cashflow (TTM)
-$19.11MPricing
Analyst Ratings
The price target is $7.733 and the stock is covered by 1 analysts.
Buy
1
Hold
0
Sell
0
Information
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck cancers, and Ligand Epitope Antigen Presentation System (LEAPS), with several product candidates under development for the potential treatment of rheumatoid arthritis. Multikine is a biological medicinal immunotherapy comprising a mixture of natural cytokines and small biological molecules. Multikine is injected around the tumor and adjacent lymph nodes for three weeks as a first-line treatment before the standard of care (SOC), which is surgery followed by either radiotherapy or chemoradiotherapy. Multikines rationale for use is to incite a locoregional immune response against the tumor.
43
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker